title: Virological suppression after use of crushed tenofovir-emtricitabine and dolutegravir tablets in a patient with HIV infection.
authors.affiliation: University of Virginia Health SystemCharlottesville, VAlrb2n@virginia.edu.
authors.forename: Lindsey
authors.initials: L
authors.lastname: Buscemi
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D004304:Dosage Forms; D004359:Drug Therapy, Combination; D000068679:Emtricitabine / Q000008:administration & dosage*; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000072230:Sustained Virologic Response; D013607:Tablets; D000068698:Tenofovir / Q000008:administration & dosage*; D019562:Viral Load / Q000187:drug effects* / Q000502:physiology; D000099226:Dolutegravir
chemical_list: D004304:Dosage Forms; D000068679:Emtricitabine; D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D013607:Tablets; D000068698:Tenofovir; D000099226:Dolutegravir